Breaking News

Agere Adds Regulatory Submission Support

December 4, 2012

Aims to expedite advancement through late stage trials

Agere Pharmaceuticals has added Regulatory Guidance to its portfolio of services. The company now supports clients in navigating, organizing and submitting regulatory documents to the FDA and other regulatory agencies. Part of the new offering includes electronic regulatory submissions to the FDA through the Electronic Submission Gateway (ESG).
 
“Outsourcing R&D as well as preclinical development has been a growing practice for years,” said Vince Foley, director of Quality for Agere. “It makes sense for an Agere client to benefit from our expertise in regulatory guidance to expedite getting their drug to the clinic and to advance through later stage clinical trials.”
 
Agere management and scientists offer extensive experience in regulatory submissions including ESG, eCTD (electronic Common Technical Document), IMPD (Investigational Medicinal Products Dossier), IND (Investigational New Drug), and Drug Master File (DMF), as well as knowledge of ICH (International Conference on Harmonization) guidelines.
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research